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Purpose: To compare the efﬁcacy of whole genome sequencing (WGS) with targeted next-generation
sequencing (NGS) in the diagnosis of inherited retinal disease (IRD).
Design: Case series.
Participants: A total of 562 patients diagnosed with IRD.
Methods: We performed a direct comparative analysis of current molecular diagnostics with WGS. We
retrospectively reviewed the ﬁndings from a diagnostic NGS DNA test for 562 patients with IRD. A subset of 46 of
562 patients (encompassing potential clinical outcomes of diagnostic analysis) also underwent WGS, and we
compared mutation detection rates and molecular diagnostic yields. In addition, we compared the sensitivity and
speciﬁcity of the 2 techniques to identify known single nucleotide variants (SNVs) using 6 control samples with
publically available genotype data.
Main Outcome Measures: Diagnostic yield of genomic testing.
Results: Across known disease-causing genes, targeted NGS and WGS achieved similar levels of sensitivity
and speciﬁcity for SNV detection. However, WGS also identiﬁed 14 clinically relevant genetic variants through WGS
that had not been identiﬁed by NGS diagnostic testing for the 46 individuals with IRD. These variants included large
deletions and variants in noncoding regions of the genome. Identiﬁcation of these variants conﬁrmed a molecular
diagnosis of IRD for 11 of the 33 individuals referred for WGS who had not obtained a molecular diagnosis through
targeted NGS testing. Weighted estimates, accounting for population structure, suggest that WGS methods could
result in an overall 29% (95% conﬁdence interval, 15e45) uplift in diagnostic yield.
Conclusions: We show that WGS methods can detect disease-causing genetic variants missed by current
NGS diagnostic methodologies for IRD and thereby demonstrate the clinical utility and additional value of
WGS. Ophthalmology 2016;123:1143-1150 ª 2016 by the American Academy of Ophthalmology. This is an open
access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Supplemental material is available at www.aaojournal.org.Deﬁning, with precision, the molecular genetic basis of
ophthalmic disorders has a profound inﬂuence on clinicians’
ability to diagnose, counsel, treat, and manage their pa-
tients.1 Inherited retinal dystrophies (IRDs) are a diverse
group of genetic disorders associated with visual
impairment. They cause visual impairment in more than 2
million people worldwide and show extreme clinical and
genetic heterogeneity.2 As such, the clinical application of
next-generation sequencing (NGS), a relatively recent
technological advance that allows fast and cost-effective
detection of genetic variation through parallel sequencing
of multiple copies of fragmented DNA,3 has transformed
IRD discovery programs and genomic diagnostics, as well 2016 by the American Academy of Ophthalmology
This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/). Published by Elsevier Inc.as for other Mendelian disorders.4 Next-generation DNA
sequencing techniques permit the analysis of genetic vari-
ants across multiple areas of the genome in a single proce-
dure. To date, the application of NGS in the clinic largely
has been limited to targeted techniques such as custom gene
panels5e7 and whole exome sequencing (WES),8,9 which
primarily restrict the analysis of genetic variation to protein-
coding regions of the genome. However, these techniques
are limited by the completeness of the genetic variation that
can be detected, including reliable identiﬁcation of large
genomic deletions or duplications that encapsulate protein-
coding regions and pathogenic variants in noncoding re-
gions of genes. Such limitations are less evident from whole1143http://dx.doi.org/10.1016/j.ophtha.2016.01.009
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detecting all types of variation across the complete human
genome.10 Targeted NGS techniques are the most
commonly used genomic diagnostic test for IRD, but
decreasing costs and increasing data interpretability have
made WGS a realistic prospect for diagnostic use in the
clinic.11e14 This is exempliﬁed by recent large-scale WGS
cohorts, for example, the “100,000 Genomes Project” in
England.15 However, the comparative beneﬁts of this
technology, in respect to current diagnostic services, have
yet to be truly delineated. The objective of this study is to
identify the additional clinical advantages of WGS for
individuals with IRD. We report the clinical ﬁndings from
a retrospective review of 562 individuals referred for
targeted NGS and a paired head-to-head comparison of
targeted NGS and WGS for 46 unrelated individuals with
clinical indications of IRD.Figure 1. Data analysis and study design summary. Overview of targeted
next-generation sequencing (NGS) diagnostic testing. *Single carrier
variant deﬁned as an individual with a pathogenic heterozygous variant
found in a gene relevant to their clinical indication of inherited retinal
disease (IRD) that is known to cause recessively inherited disease. WGS ¼
whole genome sequencing.Methods
Sampling and Study Design
Targeted Next-Generation Sequencing Testing. The retrospec-
tive review included the ﬁrst 562 individuals referred with IRD for
clinically accredited targeted NGS. All individuals underwent
clinical analysis of genetic variation within 105 genes known to
underpin IRD (Table 1, available at www.aaojournal.org).5 The
included individuals were not knowingly related and had been
referred from worldwide ophthalmic institutions. We analyzed
the information available in the molecular diagnostic report and
genetic variant ﬁles, including analysis of variant consequences
and pathogenicity, clinical outcome, and carrier status.
Phenotypeegenotype correlations were elucidated from the
scientiﬁc literature, including those referenced at the Retinal
Information Network.16 All analyses were conducted at the UK
Manchester Centre for Genomic Medicine (MCGM).
Comparison of Whole Genome Sequencing and Targeted
Next-Generation Sequencing Testing: Variant Detection
Accuracy. To determine the ability of targeted NGS and WGS to
detect single nucleotide variants (SNVs), we performed indepen-
dent assessments of the sensitivity and speciﬁcity of the 2 tech-
niques using control samples. We obtained control samples from
the Coriell Institute for Medical Research Biorepositories in May
2013, which had been anonymized with unique catalog identiﬁers.
Ethical permission was granted for the use of control samples to
improve genomic diagnostic services, in line with the National
Human Genome Research Institute Assurance Form for Bio-
materials (B-031709, available at http://www.catalog.coriell.org).
All control samples had publically available genotype data gener-
ated through the Illumina OMNI v2.5 microarray, a technique that
identiﬁes genotypes at approximately 2.5 million prespeciﬁed lo-
cations across the genome. We compared genotypes from the
Illumina OMNI v2.5 microarray (available for each sample at ftp://
ftp.sanger.ac.uk) with genotype calls from the targeted NGS and
WGS pipelines. This was performed for 4 samples using targeted
NGS through the Illumina HiSeq sequencing platform and 6
samples using WGS.
We calculated the sensitivity and speciﬁcity of targeted NGS
and WGS to detect SNVs compared with the Illumina OMNI v2.5
microarray as described previously: sensitivity, the ability to detect
SNVs identiﬁed by the Illumina OMNI v2.5 microarray, and
speciﬁcity, the ability to identify homozygous reference sites
identiﬁed by the Illumina OMNI v2.5 microarray.17 For the1144clinically analyzed region of 105 genes surveyed by both
targeted NGS and WGS, we were able to compare genotypes
with the Illumina OMNI v2.5 microarray for 2714 genotyped
sites using targeted NGS (616 SNVs and 2098 homozygous
reference sites) and 4166 genotyped sites using WGS (928 SNVs
and 3238 homozygous reference sites). All discordant sites were
assessed via Sanger sequencing,18 the “gold standard”
genotyping technique.
Comparison of Whole Genome Sequencing and Targeted
Next-Generation Sequencing Testing: Diagnostic Utility. The
major motivation for this research was to assess whether WGS
alters the number of individuals with a molecular diagnosis in
comparison with currently delivered targeted genomic diagnostics.
To address this question, we performed a paired head-to-head
comparison between targeted NGS and WGS for 46 unrelated in-
dividuals with a clinical indication of IRD. All 46 individuals had
been phenotypically assessed in a single institution. The cohort
referred for WGS included the suite of possible clinical outcomes
from targeted NGS testing (Fig 1). For each of the 46 individuals,
we undertook consecutive genomic screening: ﬁrst, targeted NGS,
and second, targeted analysis of WGS data. For each individual, we
assessed whether targeted NGS and WGS identiﬁed the same
clinically relevant mutations and achieved the same clinical
outcome.
Ethical permission for WGS was sought and granted for a
single center, MCGM. Ethics Committee approval for this study
was obtained through the REGARD study (Greater Manchester
West Research Ethics Committee reference number: 11/NW/0421).
Of the 562 individuals referred for targeted NGS testing, 126 were
referred by clinicians at the MCGM, and 59 had appropriate con-
sent for research genomics through the REGARD study. We
excluded 13 of the 59 individuals on the basis of the quality and
Table 3. Clinical Indications of Patients Referred for Targeted
Next-Generation Sequencing and Whole Genome Sequencing
Clinical Diagnosis
No. of Cases Referred
for Targeted NGS
No. of Cases
Referred for
WGS
RP or rod-cone dystrophy 268 20
Leber congenital amaurosis or
early onset rod-cone dystrophy
78 4
Other (indication not included
in this list, or not deﬁned)
43 5
Stargardt disease or macular
dystrophy
49 5
Usher syndrome 41 8
Cone-rod dystrophy 39 3
Achromatopsia or cone
dystrophy
27 1
Syndromic ciliopathies 8 -
Familial exudative
vitreoretinopathy
5 -
Choroideremia 4 -
NGS ¼ next-generation sequencing; RP ¼ retinitis pigmentosa; WGS ¼
whole genome sequencing.
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referred for WGS, which was performed using 10 mg of DNA that
had been extracted from patient blood samples and stored during
targeted NGS testing. All individuals referred for WGS were
analyzed on a singleton basis and had received a clinical outcome
from targeted NGS before January 2014. Targeted analysis was
performed on WGS data within hierarchical lists of genes known to
cause IRD (ﬁrst for 105 genes, Table 1; second for 180 genes,
Table 2, both available at www.aaojournal.org). The
methodologies of this research adhered to the tenets of the
Declaration of Helsinki.
Sequencing and Variant Calling
Targeted Next-Generation Sequencing Testing. Targeted NGS
diagnostic testing was performed for 562 patient DNA samples.
The pipeline involved (i) enrichment of relevant genomic regions,
(ii) multiplexed high-throughput DNA sequencing (NGS), (iii)
clinical bioinformatics (demultiplexing, alignment to the hg19
reference genome, variant calling and annotation), and (iv) clinical
analysis and determination of pathogenicity of rare genomic
variations.
The targeted capture region was deﬁned as the protein-coding
regions 50 base pairs of speciﬁed transcripts for 105 genes
(Table 1, available at www.aaojournal.org) and a speciﬁc
noncoding region of the CEP290 gene. Enrichment was
performed using an Agilent SureSelect Custom Design target-
enrichment kit (Agilent, Santa Clara, CA). Next-generation
sequencing was performed using the manufacturer protocols for
the ABI SOLiD 5500 platform (n ¼ 255; Life Technologies Cor-
poration, Carlsbad, CA) and the Illumina HiSeq 2000/2500 plat-
form (n ¼ 307; Illumina, Inc., San Diego, CA). Clinical
bioinformatics was performed using a variety of open-source
software, including Lifescope, CASAVA v.1.8.2., BWA-short
v.0.6.219 and GATK-lite v2.0.39.20 Annotations were performed
using v68 of the Ensembl database.
Whole Genome Sequencing. Whole genome sequencing was
performed on 52 DNA samples (6 controls, 46 patients) by
Complete Genomics (Mountain View, CA) as described previ-
ously.21 Bioinformatics (alignment to the hg19 reference genome,
local de novo assembly, and variant calling) was performed using
version 2.5 of the Complete Genomics pipeline.22 Variants were
restricted to those in speciﬁed lists of genes (ﬁrst for 105 genes,
Table 1; second for 180 genes, Table 2, both available at
www.aaojournal.org), and their presence was conﬁrmed through
an alternative method before they were clinically reported.
Determining Clinical Outcomes
The clinical analysis of genomic variation requires the interpreta-
tion of pathogenicity, the assessment of genetic inheritance pat-
terns, and detailed phenotypic analysis (Fig 1). These analyses
determine the clinical outcome of diagnostic molecular testing,
which may (i) deﬁne an unequivocal clinical diagnosis, (ii)
conﬁrm a likely clinical diagnosis, or (iii) exclude, challenge, or
fail to conﬁrm a clinical diagnosis. The detailed clinical
algorithms used in each stage of the analysis procedure are
included in the Appendix (available at www.aaojournal.org).
Variants identiﬁed by WGS also were classiﬁed in accordance
with recent clinical guidelines for genetic variant interpretation.23
Projected Impact of Clinical Whole Genome
Sequencing
To predict the potential impact of the WGS pipeline on current
clinical practice, we derived a weighted estimate of the diagnosticyield based on the prevalence of clinical outcomes observed in the
population of 562 patients referred for targeted NGS testing and the
sampling proportions and diagnostic yield in the stratiﬁed sample
of 46 patients referred for both targeted NGS testing and WGS.
The 95% conﬁdence interval (CI) was obtained by simulating
draws from a binomial distribution for each of the estimated pro-
portions and computing the 2.5 and 97.5 percentiles of the distri-
bution of the resultant uplift estimates. R software was used to
generate 10 000 simulations.
Results
Patient Characteristics
A total of 562 patients (male, n ¼ 299; female, n ¼ 263) were
referred for targeted NGS testing from healthcare institutions in 12
different countries; the majority were referred from within the
United Kingdom (78%; n ¼ 436). Clinical indications of diagnoses
derived from 1 of 10 distinct forms of IRD, the most common
being retinitis pigmentosa (RP) (48%) (Table 3). All of the 46
patients who underwent WGS (male, n ¼ 24; female, n ¼ 22)
were referred by clinicians in a single center. Of these, 34 had
nonsyndromic IRD. Among the remaining 12 patients, additional
clinical features suggesting a syndromic form of IRD included
hearing loss, n ¼ 9; hearing loss and renal failure, n ¼ 1;
hearing loss and gross motor delay, n ¼ 1; and autism, learning
difﬁculties and developmental delay, n ¼ 1. Nonsyndromic RP
also was the most common IRD subtype among the 46 patients
referred for WGS (Table 3), accounting for 43% of the cohort.
Coverage, Sensitivity, and Speciﬁcity of Whole
Genome Sequencing and Targeted Next-
Generation Sequencing
We deﬁned coverage as the number of times a single nucleotide
was sequenced by unique and independent NGS reads. We directly
compared the coverage achieved by targeted NGS and WGS for
the protein coding region of the 105 genes surveyed by both
techniques and found that targeted NGS and WGS achieved 20
average coverage for 98.4% (n ¼ 562) and 98.5% (n ¼ 52),1145
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20 coverage for 96.5% of the whole genome and 98.0% of the
protein-coding region of the genome (n ¼ 52) (Table 4, available at
www.aaojournal.org). However, WGS generated inconsistent
coverage at 20 across repetitive regions of the genome, such
as RPGRorf15 (mean ¼ 58.0%, min/max ¼ 39.0/78.1%, n ¼ 52)
(Table 4, available at www.aaojournal.org).
Compared with the Illumina OMNI v2.5 microarray genotyped
sites within the protein-coding regions of 105 genes, WGS (sur-
veyed SNVs, n ¼ 928) and targeted NGS (surveyed SNVs, n ¼
616) achieved 100% sensitivity for SNV detection and 99.9%
(surveyed sites, n ¼ 3238) and 100% (surveyed sites, n ¼ 2098)
speciﬁcity for SNV detection, respectively. On the basis of our
ﬁndings from Sanger sequencing discordant sites, an inherent error
rate of 2.16% in the Illumina OMNI v2.5 microarray, we estimate
that the WGS pipeline achieved 97.8% sensitivity and 99.3%
speciﬁcity for SNV detection for the protein-coding and noncoding
regions of 180 genes analyzed during the second tier of analysis
(Tables 5e7, available at www.aaojournal.org). Likewise, we
estimate that WGS achieved 97.7% sensitivity and 98.9%
speciﬁcity for SNV detection for the whole genome (Table 8,
available at www.aaojournal.org).
Summary of Findings from Targeted Next-
Generation Sequencing for 562 Individuals with
Inherited Retinal Disease
Targeted NGS testing identiﬁed 416 genetic variants likely or
highly likely to account for disease presentation in 281 patients
(50%) (Fig 2A), including 53 autosomal dominant cases, 1 X-
linked dominant case, 13 X-linked recessive cases, and 214
autosomal recessive cases (91 homozygous cases and 123
compound heterozygous cases).
The Illumina HiSeq sequencing platform achieved 20
coverage across signiﬁcantly more of the clinically analyzed region
of 105 genes for referred individuals than the ABI SOLiD
sequencing platform (HiSeq ¼ 99.000.01, SOLiD ¼
97.630.06, P < 0.0001). However, there was no signiﬁcant dif-
ference in the diagnostic success rate of the 2 sequencing platforms
(HiSeq ¼ 48%, SOLiD ¼ 52%, P ¼ 0.37).
Of the 562 referred patients, 28% (n ¼ 158) were reported to
carry heterozygous variants that would be expected to cause dis-
ease if present in a compound heterozygous or homozygous state
(i.e., carrier status of recessive trait). For 61 of these patients
(39%), the identiﬁcation of clinically relevant variants in other
genes achieved an alternative molecular diagnosis (dominant cases,
n ¼ 15; recessive cases, n ¼ 46). The remaining 97 patients (61%)
did not receive a molecular diagnosis, 59 of whom had heterozy-
gous variants in genes known to be a cause of their speciﬁc dis-
order (Fig 2A; Table 3 shows a list of all IRD subtypes).
Head-to-Head Comparison of Whole Genome
Sequencing and Targeted Next-Generation
Sequencing for 46 Individuals with Inherited
Retinal Disease
Forty-six of the 562 patients who had been analyzed by targeted
NGS were subsequently analyzed using a WGS pipeline, including
13 individuals with a conﬁrmed or provisionally conﬁrmed mo-
lecular diagnosis and 33 individuals without a molecular diagnosis.
Whole genome sequencing found more molecular diagnoses than
were initially identiﬁed by targeted NGS techniques (targeted
NGS ¼ 13, WGS ¼ 24). The increase in molecular diagnoses was
underpinned by the detection of additional clinically relevant var-
iants accounting for or likely accounting for disease presentation in114611 of the individuals without a molecular diagnosis from targeted
NGS (Table 9).
For 13 individuals with a molecular diagnosis from targeted
NGS, we assessed whether WGS identiﬁed the same molecular
diagnosis. We identiﬁed 10 “clearly pathogenic” and 9 “likely
pathogenic” variants (missense, n ¼ 9; nonsense, n ¼ 6; frameshift,
n ¼ 4) (Table 10, available at www.aaojournal.org) accounting for
10 conﬁrmed molecular diagnoses and 3 provisional molecular
diagnoses, all of which had been identiﬁed by targeted NGS.
Through WGS, we also identiﬁed 2 “likely pathogenic”
heterozygous deletions that had not been identiﬁed through
targeted NGS testing (Table 9) (067429 and 12008422). A
heterozygous deletion in USH2A was identiﬁed in trans to a
missense variant that had been determined as homozygous and
“likely pathogenic” through targeted NGS. This ﬁnding reﬁned
the molecular diagnosis for the referred individual (Table 10,
available at www.aaojournal.org) (12008422). A heterozygous
deletion in RPGRIP1 was identiﬁed in an individual referred
with sporadic RP. This ﬁnding was not thought to contribute to
the molecular diagnosis for the referred individual (Table 10,
available at www.aaojournal.org) (067429) because “clearly
pathogenic” and “likely pathogenic” variants were found in
another gene, EYS, and mutations in RPGRIP1 are expected to
cause recessively inherited disease.24 Both identiﬁed RPGRIP1
and USH2A heterozygous deletions have counseling implications
for the referred individuals.
For 33 individuals without a molecular diagnosis from targeted
NGS, we found that the WGS pipeline identiﬁed 9 “likely patho-
genic” variants and 3 “clearly pathogenic” variants that had not
been identiﬁed by targeted NGS (Table 9). These included 3 large
deletions encapsulating protein-coding regions, 5 variants in non-
coding regions of genes, 3 complex insertion and deletion events,
and 1 variant in an additional gene implicated in the onset of IRD
that is not included in the 105 geneetargeted NGS test. The var-
iants underpinning IRD in each of the 46 patients with WGS data
have been submitted to the ClinVar database (Accession numbers:
SCV00259071-SCV000259109). We outline the patient beneﬁt
provided by WGS for an exemplar individual in the included Case
Study.
If the WGS pipeline is applied to all 562 patients referred for
targeted NGS testing, and assuming the same rate of mutation
discovery, we calculate that the WGS pipeline could provide a 29%
(95% CI, 15e45) uplift in diagnostic yield compared with current
targeted NGS services (Fig 2B). However, much of this uplift also
could be achieved by straightforward modiﬁcations to the targeted
NGS bioinformatics pipeline (12%, 95% CI, 5e20) (Fig 2B),
including the use of additional variant calling software (e.g.,
Pindel25) and corrections to the regions of the genome that are
clinically analyzed (e.g., extension of the analysis to known
pathogenic variants in noncoding regions of the genome)
(Table 11, available at www.aaojournal.org).
Discussion
Our ability to interrogate the human genome in a clinical
setting has transformed rapidly over the past decade. The
present day genomic diagnostic laboratory now hosts an
arsenal of high-throughput DNA surveillance techniques.
These include DNA sequencing speciﬁcally targeted to
areas of the genome already known to harbor disease-
causing variation, for example, the targeted sequencing
(described in this article) of protein-coding regions for 105
genes implicated in the onset of IRD. Whole genome
sequencing now offers an opportunity to analyze variation
Figure 2. A, Clinical outcome of diagnostic next-generation sequencing (NGS) testing for 562 individuals. Diagnosed, individuals with a molecular
diagnosis. Undiagnosed, individuals without a molecular diagnosis. Single carrier variant, individuals who are heterozygous for a “clearly pathogenic” or
“likely pathogenic” variant in a gene associated with recessive retinal dystrophy; no second variant was identiﬁed. Other variants in additional genes may or
may not be determined to cause the phenotype, this refers to diagnosed and single carrier variant and undiagnosed and single carrier variant, respectively. B,
Projected impact of whole genome sequencing (WGS) on clinical molecular diagnostics. A weighted biased estimate with 95% conﬁdence intervals (CIs) of
the projected increase in molecular diagnostic yield: targeted NGS, number of individuals with a molecular diagnosis through targeted NGS diagnostics;
bioinformatics adjustments, the number of individuals expected to receive a molecular diagnosis after alterations to the bioinformatics pipeline for targeted
NGS diagnostics; WGS, the number of individuals expected to have a molecular diagnosis if WGS were to be applied to the 562 referred patients.
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in cost and increases in data interpretability offers a potential
further step-change in the clinical evaluation of genetic
variation for rare (Mendelian) disease, including the highly
heterogeneous group of IRD. Whole genome sequencing
has the potential to become an additional tool for genome
diagnostic laboratories. However, the additional advantages
of WGS over current genomic diagnostic technologies
(targeted NGS) for ophthalmic disorders are not yet fully
quantiﬁed, because formal comparative analyses of the 2
techniques have not been undertaken.
We surveyed 562 patients referred for targeted NGS with
clinical indications of IRD (Table 3) and established a
molecular diagnosis in 50% of cases, a rate consistent
with other published ﬁgures.6e8,26 Our ﬁndings conﬁrm
the power of targeted NGS approaches to provide a diag-
nosis for individuals with IRD. Although the transition from
the ABI SOLiD sequencing platform to the Illumina HiSeqsequencing platform did not increase diagnostic yield for
referred patients, it has increased the clarity of diagnostic
reporting because it achieved more uniform sequencing
coverage and a greater percentage of DNA nucleotides
sequenced at speciﬁed diagnostic thresholds. Of note,
among those with a positive diagnosis from targeted NGS,
5% carry single heterozygous pathogenic variants in genes
known to cause recessive IRD and identiﬁed in genes
relevant to their speciﬁc phenotype. Such carrier variants are
at a higher frequency in individuals without a molecular
diagnosis (Fig 2A), leading to uncertainty in diagnosis. This
highlights potential limitations of targeted NGS
technologies to deﬁne the true diversity of genetic
variation underpinning IRD. To assess these limitations,
46 of the 562 patients underwent WGS to compare the
mutation detection rates and molecular diagnostic yield
with those achieved by targeted NGS. We clearly
demonstrate that WGS pipelines have a greater power1147
Table 9. Clinically Relevant Variants Identiﬁed by Whole Genome Sequencing That Were Not Detected by Targeted Next-Generation
Sequencing Testing
Patient ID Gene Zygosity cDNA Protein Genomic Coordinates (hg19)
Large Deletions
12002355 PCDH15 Heterozygous c.-189197_c.610-5166del Removes start codon Chr10:56,094,632-56,613,219
065240 MERTK Homozygous c.-8163_c.1145-1213del Removes start codon Chr2:112,648,150-112,739,206
11012351 GPR98 Heterozygous c.16079-1455_c.16196þ155del p.(Ser5361Profs*25) Chr5:90,109,981-90,111,708
12008422 USH2A Heterozygous c.6326-3582_6658-1028del p.(Asp2109Glyfs*11) Chr1:216,167,537-216,177,486
067429 RPGRIP1 Heterozygous c.2710þ485_3238þ810del p.(Gly904_Asn1079del) Chr14:21,794,817-21,799,356
Intronic Variants
09006916 ABCA4 Heterozygous c.5461-10T>C n/a Chr1:94,476,951
12007903 ABCA4 Heterozygous c.5461-10T>C n/a Chr1:94,476,951
11012351 GPR98 Heterozygous c.1239-8C>G n/a Chr5:89,924,371
Insertions-Deletions
11001193 PDE6B Heterozygous c.1923_1969delinsTCTGGG p.(Asn643Glyfs*29) Chr4:654,564-657,607
11013807 USH2A Heterozygous c.5614delinsTTAACTTGGCAT p.(Ala1872Metfs*4) Chr1:216,246,601
12003183 CRX Heterozygous c.648delC p.(Ser216Argfs*3) Chr19:48342972
Missed by Informatics Errors
065238 ABCA4 Heterozygous c.5714þ5G>A n/a Chr1:94,476,351
13012708 ABCA4 Heterozygous c.5714þ5G>A n/a Chr1:94,476,351
Variants in Additional 75 Genes
11012959 TRPM1 Homozygous c.707T>C p.(Leu236Pro) Chr15:31,358,296
n/a ¼ not available.
*Indicates a premature termination during protein translation. All variant conﬁrmations are available online in Figures 4 to 17, available at
www.aaojournal.org.
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spectrum of genetic variants (Table 9), including large
structural variation, noncoding mutations excluded from
targeted NGS analysis regions, and mutations in genes
excluded from targeted capture. The deletions identiﬁed
by the WGS pipeline ranged from <1.7 Kb to >520 Kb
in size, and the identiﬁcation of breakpoints in noncoding
regions of the genome permitted subsequent cost-effective
clinical validation (Fig 3). Therefore, this work highlights
the beneﬁt of a single diagnostic technique for IRD that
can accurately identify disease-causing small variation and
large structural variation encompassing protein-coding re-
gions of genes (see Case Study for illustrative example).
Traditionally, this has been possible only through a com-
bination of 2 or more diagnostic modalities because soft-
ware to detect large structural variation from targeted NGSFigure 3. Sanger sequencing chromatogram showing the breakpoints of a
heterozygous deletion removing a single exon from the reading frame of the
GPR98 gene.
1148data (e.g., ExomeDepth27) remains unvalidated in a clinical
diagnostic context.
From a diagnostic viewpoint, we also assessed the
sensitivity and speciﬁcity of targeted NGS and WGS to
detect genetic variation of single nucleotides (SNVs), using
6 control samples. We compared genotypes generated
through targeted NGS and WGS with those publically
available from the Illumina OMNI v2.5 microarray (avail-
able at ftp://ftp.sanger.ac.uk) and found that the WGS
pipeline achieved similar sensitivity and speciﬁcity levels
for SNV detection to targeted NGS and demonstrated better
sensitivity and speciﬁcity levels for SNV detection than
those reported for WES pipelines.17 This is consistent with
data suggesting that WGS is a better tool for genetic variant
detection in protein-coding regions than WES.10,28 It is of
note that both techniques shared limitations, for example,
both targeted NGS and WGS were unable to reproducibly
survey the repetitive and AG rich protein-coding region of
RPGR (orf15) (Table 4, available at www.aaojournal.org),
which accounts for 75% of X-linked RP.29
The data underline the clinical utility of NGS modalities
for diagnosing IRD and conﬁrm the considerable utility of
targeted NGS as a diagnostic tool for IRD. Furthermore, the
analysis of WGS for a small cohort of individuals has
improved the routine diagnostic services provided for in-
dividuals referred with IRD. The costs and data burdens
associated with WGS remain substantial; therefore, the
continual translation of ﬁndings from WGS into currently
delivered molecular diagnostics will, in the short term,
provide the best route for developing more sensitive diag-
nostic tests for IRD. However, in assessing the limitations of
current diagnostic modalities, and in looking to the future,
we demonstrate the additional beneﬁts of clinical WGS in
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burdens associated with WGS decrease sufﬁciently, whole
genome-based sequencing pipelines are likely to become
routinely used in the diagnosis of IRD.
Case Study: Usher Syndrome
A female presented with RP and congenital deafness, sug-
gesting a clinical diagnosis of Usher syndrome. There was
no family history.
Targeted NGS testing identiﬁed no molecular cause. The
patient carried the following:i) a “likely pathogenic” heterozygous variant in
IDH3B, c.184G>T, p.(Glu62*).Mutations in IDH3B have been associated with auto-
somal recessive nonsyndromic RP.30 Therefore, this ﬁnding
was concluded not to contribute to the molecular diagnosis
of IRD for this individual.
Analysis of WGS data also identiﬁed the following:ii) a “likely pathogenic” heterozygous GPR98 non-
coding variant, c.1239-8C>G
iii) a “likely pathogenic” heterozygous deletion,
c.16079-1456_ c.16196þ155del p.(Ser5361-
Profs*25), removing a protein-coding region (exon)
of GPR98 (Fig 3) and expected to cause premature
termination of protein translation.Homozygous and compound heterozygous mutations in
GPR98 cause Usher syndrome.2 These ﬁndings were
concluded to conﬁrm a diagnosis of autosomal recessive
Usher syndrome.
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